Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease
Journal of Clinical Psychopharmacology2009Vol. 29(5), pp. 484–487
Citations Over TimeTop 16% of 2009 papers
Leigh J. Beglinger, Williams H. Adams, Henry L. Paulson, Jess G. Fiedorowicz, Douglas R. Langbehn, Karen Duff, Anne Leserman, Jane S. Paulsen
Abstract
Atomoxetine demonstrated no advantages over placebo for primary or secondary outcomes. Although atomoxetine was not effective at improving attention at this dose, its safety and tolerability were similar to other studies.
Related Papers
- → Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder(2002)336 cited
- → Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis(2005)107 cited
- → Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder(2006)104 cited
- → Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder(2015)12 cited
- → Atomoxetine(2003)